Drug intelligence / Profile preview

Tongxinshu capsule

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Modality: Small Molecules
Administration: Oral

Overview

Tongxinshu capsule is a Traditional Chinese Medicine (TCM) composed of several herbal ingredients, including *Salvia miltiorrhiza* extract, *Ligusticum chuanxiong*, *Hippophae rhamnoides*, and flavonoids. It is indicated for the treatment of stable angina pectoris in coronary heart disease patients presenting with Qi deficiency and blood stasis syndrome. The drug is designed to benefit Qi, promote blood circulation, resolve blood stasis, and alleviate pain, thereby improving symptoms such as chest pain, palpitations, and shortness of breath associated with this condition. Clinical trials have shown its efficacy in improving angina attacks, overall clinical symptoms, and quality of life for patients with stable angina pectoris.

Brand names: 通心舒胶囊

Beyond the preview

Go deeper on Tongxinshu capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongxinshu capsule.

Explore the full profile